65,437 trials
Alzheimer Disease · Dementia Alzheimers · Dementia of Alzheimer Type
Primary: Cumulative Total of New Antipsychotic Pill-days Prescribed — 12569; 25916 New antipsychotic prescription days
Human Immunodeficiency Virus
Primary: Tenofovir-diphosphate (TFV-DP) Concentration — 217; 1041; 578; 789 femtomoles
Aortic Aneurysm, Abdominal
Primary: Technical Success: — 28 participants
Shame
Primary: Willingness to Communicate — 3.3 score on a scale
Non-squamous, Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR): Based on Charted/Physician-reported Disease Response — 37.5; 76.3; 43.8; 77.8 percentage of patients
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster…
HIV/AIDS · Depression · Anxiety
Primary: Feasibility of Recruitment — 92 participants
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants
HIV Infection
Primary: Number of Participants With Adverse Events — 5; 15; 7; 4 Participants
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Post Partum Depression
Primary: Depression Symptoms at 2 Months (QIDS SR-16 ≥ 11) — 32; 26 Participants
COVID-19
Primary: Seroresponse — 253; 250 Participants
Well-being
Primary: Number of Participants Assessed for the Feasibility of Study Procedures — 27; 19; 15; 10 Participants
Methicillin-Resistant Staphylococcus Aureus · Bacterial Infections · Staphylococcal Skin Infections
Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants
Acute Myeloid Leukemia
Primary: Safety and Tolerability — 42; 3; 3; 6 Participants